Share on StockTwits

Intersect ENT (NASDAQ: XENT) received a number of price target changes and ratings updates during the last week:

  • Intersect ENT is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $22.00 price target on the stock.
  • Intersect ENT is now covered by analysts at Piper Jaffray. They set an “overweight” rating and a $20.00 price target on the stock.
  • Intersect ENT is now covered by analysts at Wedbush. They set an “outperform” rating and a $18.00 price target on the stock.
  • Intersect ENT is now covered by analysts at Leerink Swann. They set an “outperform” rating and a $20.00 price target on the stock.

Shares of Intersect ENT Inc (NASDAQ:XENT) traded up 0.49% on Tuesday, hitting $16.45. The stock had a trading volume of 52,711 shares. Intersect ENT Inc has a 52-week low of $12.02 and a 52-week high of $16.78. The stock has a 50-day moving average of $13.95 and a 200-day moving average of $13.95. The company’s market cap is $370.1 million.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.